Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fangxin Hong

Showing results (51-60 of 101) with videos related to

Pageof 11
Sort By:
Leukemia & Lymphoma|June 22, 2013
Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)Kristen Ganjoo, Fangxin Hong, Sandra J Horning, et al.
Breast Cancer Research and Treatment|October 16, 2019
The Jacki Jacket after mastectomy with reconstruction: a randomized pilot studyDonna L Berry, Traci M Blonquist, Barbara Halpenny, et al.
Psycho-Oncology|January 24, 2019
The effect of a lifestyle risk reduction intervention on lifestyle adherence and health-related quality of life in nonsmall cell lung cancer survivors: Feasibility study outcomesMary E Cooley, Traci M Blonquist, Fangxin Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499Mitchell R Smith, Hailun Li, Leo Gordon, et al.
Gynecologic Oncology|September 3, 2022
How does patient-centered communication in ovarian cancer care enhance patient well-being? A mixed methods studyRachel A Pozzar, Niya Xiong, Fangxin Hong, et al.
British Journal of Haematology|April 1, 2015
Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404)Lode J Swinnen, Hailun Li, Andrew Quon, et al.
Blood Cancer Journal|March 14, 2018
Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine eraRebecca L King, Grzegorz S Nowakowski, Thomas E Witzig, et al.
Gynecologic Oncology|August 29, 2021
Perceived patient-centered communication, quality of life, and symptom burden in individuals with ovarian cancerRachel A Pozzar, Niya Xiong, Fangxin Hong, et al.
BMC Cancer|July 13, 2014
The electronic self report assessment and intervention for cancer: promoting patient verbal reporting of symptom and quality of life issues in a randomized controlled trialDonna L Berry, Fangxin Hong, Barbara Halpenny, et al.
Urology Practice|August 5, 2021
Evaluating Clinical Implementation Approaches for Prostate Cancer Decision SupportDonna L Berry, Fangxin Hong, Barbara Halpenny, et al.
Pageof 11

Showing results (51-60 of 101) with videos related to

Sort By:
Pageof 11
Leukemia & Lymphoma|June 22, 2013
Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)Kristen Ganjoo, Fangxin Hong, Sandra J Horning, et al.
Breast Cancer Research and Treatment|October 16, 2019
The Jacki Jacket after mastectomy with reconstruction: a randomized pilot studyDonna L Berry, Traci M Blonquist, Barbara Halpenny, et al.
Psycho-Oncology|January 24, 2019
The effect of a lifestyle risk reduction intervention on lifestyle adherence and health-related quality of life in nonsmall cell lung cancer survivors: Feasibility study outcomesMary E Cooley, Traci M Blonquist, Fangxin Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499Mitchell R Smith, Hailun Li, Leo Gordon, et al.
Gynecologic Oncology|September 3, 2022
How does patient-centered communication in ovarian cancer care enhance patient well-being? A mixed methods studyRachel A Pozzar, Niya Xiong, Fangxin Hong, et al.
British Journal of Haematology|April 1, 2015
Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404)Lode J Swinnen, Hailun Li, Andrew Quon, et al.
Blood Cancer Journal|March 14, 2018
Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine eraRebecca L King, Grzegorz S Nowakowski, Thomas E Witzig, et al.
Gynecologic Oncology|August 29, 2021
Perceived patient-centered communication, quality of life, and symptom burden in individuals with ovarian cancerRachel A Pozzar, Niya Xiong, Fangxin Hong, et al.
BMC Cancer|July 13, 2014
The electronic self report assessment and intervention for cancer: promoting patient verbal reporting of symptom and quality of life issues in a randomized controlled trialDonna L Berry, Fangxin Hong, Barbara Halpenny, et al.
Urology Practice|August 5, 2021
Evaluating Clinical Implementation Approaches for Prostate Cancer Decision SupportDonna L Berry, Fangxin Hong, Barbara Halpenny, et al.
Pageof 11